GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Biogen BIIB · USD

Health Care · Biotechnology · US listing · 🇺🇸 United States

S&P 500

Compare

254.87

+2.63%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$9.89bn

FY2016FY2025

Net income

$1.29bn

FY2016FY2025

Free cash flow

$2.02bn

FY2016FY2025

Shareholders' equity

$18.26bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$9.89bn$9.68bn$9.84bn$10.17bn$10.98bn$13.45bn$14.38bn$13.45bn$12.27bn$11.45bn
Gross profit$7.52bn$7.47bn$7.43bn$7.89bn$8.87bn$11.64bn$12.42bn$11.64bn$10.64bn$9.97bn
Research and development$1.75bn$2.02bn$2.46bn$2.23bn$2.50bn$3.98bn$2.27bn$2.60bn$2.25bn$1.97bn
Operating income$2.79bn$2.65bn$2.17bn$3.22bn$3.50bn$4.97bn$7.56bn$6.57bn$5.58bn$5.66bn
Net income$1.29bn$1.63bn$1.16bn$3.05bn$1.56bn$4.00bn$5.89bn$4.43bn$2.54bn$3.70bn
Diluted earnings per share8.7911.197.9720.8710.3724.8531.4921.6111.9216.92

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$29.44bn$28.05bn$26.84bn$24.55bn$23.88bn$24.62bn$27.23bn$25.29bn$23.65bn$22.88bn
Cash and short-term investments$3.82bn$2.38bn$1.05bn$4.89bn$3.80bn$2.61bn$4.48bn$3.54bn$3.69bn$4.89bn
Total liabilities$11.18bn$11.33bn$12.05bn$11.16bn$12.98bn$13.92bn$13.89bn$12.25bn$11.04bn$10.74bn
Debt$6.29bn$6.30bn$6.94bn$6.28bn$7.27bn$7.43bn$5.96bn$5.94bn$5.94bn$6.52bn
Shareholders' equity$18.26bn$16.72bn$14.80bn$13.40bn$10.90bn$10.70bn$13.34bn$13.04bn$12.61bn$12.14bn
Shares outstanding147m146m146m146m150m161m187m205m213m219m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$2.20bn$2.88bn$1.55bn$1.38bn$3.64bn$4.23bn$7.08bn$6.19bn$4.55bn$4.59bn
Capital spending−$185.4m−$359.8m−$311.4m−$243.2m−$294.9m−$551.8m−$669.5m−$886.1m−$1.96bn−$727.7m
Free cash flow$2.02bn$2.52bn$1.24bn$1.14bn$3.35bn$3.68bn$6.41bn$5.30bn$2.59bn$3.86bn

Latest quarters

By quarter end

Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024Jun 2024Mar 2024
Revenue$2.28bn$2.53bn$2.65bn$2.43bn$2.45bn$2.47bn$2.46bn$2.29bn
Gross profit$1.78bn$1.86bn$2.04bn$1.80bn$1.87bn$1.83bn$1.92bn$1.75bn
Operating income$465.0m$694.4m$925.0m$679.0m$570.1m$559.3m$773.3m$646.4m
Net income−$48.9m$466.5m$635.0m$240.5m$267.0m$389.0m$583.6m$393.4m
Diluted earnings per share-0.333.174.331.641.832.664.002.70
Cash from operations$511.0m$1.27bn$160.0m$259.0m$761.0m$936.0m$625.0m$553.0m
Capital spending−$60.0m−$51.0m−$26.0m−$47.0m−$66.0m−$130.0m−$42.0m−$120.0m
Free cash flow$451.0m$1.22bn$134.0m$212.0m$695.0m$806.0m$583.0m$433.0m
Total assets$29.44bn$29.21bn$28.33bn$28.03bn$28.05bn$28.31bn$26.80bn$26.57bn
Cash and short-term investments$3.82bn$3.96bn$2.76bn$2.60bn$2.38bn$1.70bn$1.91bn$1.07bn
Debt$6.29bn$6.29bn$6.28bn$4.55bn$4.55bn$4.55bn$6.29bn$6.29bn
Shareholders' equity$18.26bn$18.21bn$17.63bn$16.98bn$16.72bn$16.36bn$15.89bn$15.21bn

Financial ratios

Data as of 23 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin70.5%76.1%74.2%77.6%80.8%86.6%
Operating margin19.1%25.7%21.3%29.7%25.4%34.6%
Net margin13.2%16.9%11.8%29.9%14.2%29.8%
Return on equity7.1%9.8%7.8%22.7%14.3%37.4%
Return on assets4.4%5.8%4.3%12.4%6.5%16.3%
Free cash flow yield7.1%9.8%5.7%5.0%11.8%13.8%
Revenue growth1.4%-1.6%-3.3%-7.4%-18.3%-6.5%
Earnings growth-20.8%40.6%-61.9%95.8%-61.1%-32.1%
Current ratio2.68x1.35x2.00x2.99x1.83x1.84x
Debt to equity0.35x0.38x0.47x0.48x0.67x0.71x
Equity ratio62.0%59.6%55.1%54.6%45.6%43.5%
Interest coverage7.63x9.95x8.49x12.24x11.01x20.90x
R&D as a share of sales19.9%25.7%27.5%25.5%31.0%33.7%
Buybacks as a share of market value-0.4%-0.3%-0.3%1.6%4.2%13.6%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue-0.9%-6.0%-0.8%
Operating income-4.7%-10.9%-5.6%
Net income-24.9%-20.2%-9.6%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin76.6%76.6%79.4%83.1%
Operating margin27.8%27.4%30.2%39.3%
Net margin14.9%18.0%19.8%26.0%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings20.013.732.513.323.19.89.413.926.715.4
Price to sales2.62.33.84.03.32.93.94.65.55.0

Market value over time

31 Oct 2016 to 22 Sept 2026, in USD

$56.52bn$33.51bn

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return16%-42%-11%20%-5%-18%3%-12%27%-3%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 3-for-1 split · 18 Jan 2001
  • 2-for-1 split · 21 Dec 1999

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.